Patents by Inventor Ravi Chari

Ravi Chari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12066246
    Abstract: Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.
    Type: Grant
    Filed: June 9, 2023
    Date of Patent: August 20, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Xiaolin Tang, Mary Kleppe, Ravi Chari, Franco Tzul
  • Publication number: 20230358470
    Abstract: Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.
    Type: Application
    Filed: June 9, 2023
    Publication date: November 9, 2023
    Inventors: Xiaolin Tang, Mary Kleppe, Ravi Chari, Franco Tzul
  • Patent number: 11713922
    Abstract: Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: August 1, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Xiaolin Tang, Mary Kleppe, Ravi Chari, Franco Tzul
  • Publication number: 20230077563
    Abstract: Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.
    Type: Application
    Filed: November 11, 2022
    Publication date: March 16, 2023
    Inventors: Xiaolin Tang, Mary Kleppe, Ravi Chari, Franco Tzul
  • Publication number: 20220403052
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: January 28, 2022
    Publication date: December 22, 2022
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Patent number: 11525629
    Abstract: Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: December 13, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Xiaolin Tang, Mary Kleppe, Ravi Chari, Franco Tzul
  • Publication number: 20210239396
    Abstract: Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.
    Type: Application
    Filed: February 4, 2021
    Publication date: August 5, 2021
    Inventors: Xiaolin Tang, Mary Kleppe, Ravi Chari, Franco Tzul
  • Publication number: 20210188996
    Abstract: Provided are formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof. The formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa·s, and the pH of the solution is 5.9 to 7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations will find use in treating CD38+ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 24, 2021
    Inventors: Sylvain Huille, Thomas Ballet, Kiran Bangari, Ravi Chari, Bernardo Perez-Ramirez, Filipe Vasco
  • Publication number: 20200385456
    Abstract: The invention provides stable aqueous formulations comprising an Aqueous Stable Dual Variable Domain Immunoglobulin (AS-DVD-Ig) protein. The invention also provides stable lyophilized formulations comprising a Lyophilized Stable Dual Variable Domain Immunoglobulin (LS-DVD-Ig) protein.
    Type: Application
    Filed: January 17, 2020
    Publication date: December 10, 2020
    Inventors: Michael Siedler, Vineet Kumar, Ravi Chari, Sonal Saluja, Vishwesh Patil
  • Publication number: 20190031783
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: March 7, 2018
    Publication date: January 31, 2019
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Publication number: 20180362629
    Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and caninized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 20, 2018
    Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
  • Patent number: 10125192
    Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: November 13, 2018
    Assignee: ZOETIS BELGIUM S.A.
    Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
  • Patent number: 10093725
    Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: October 9, 2018
    Assignee: ZOETIS BELGIUM S.A.
    Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
  • Patent number: 9944720
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 17, 2018
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Patent number: 9840554
    Abstract: Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: December 12, 2017
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Diana Bowley, Lucia Eaton, Feng Dong, Lorenzo Benatuil, Tariq Ghayur, Ravi Chari, Matthew Rieser, Anca Clabbers
  • Publication number: 20170210796
    Abstract: The invention provides stable aqueous formulations comprising an Aqueous Stable Dual Variable Domain Immunoglobulin (AS-DVD-Ig) protein. The invention also provides stable lyophilized formulations comprising a Lyophilized Stable Dual Variable Domain Immunoglobulin (LS-DVD-Ig) protein.
    Type: Application
    Filed: November 4, 2016
    Publication date: July 27, 2017
    Inventors: Michael SIEDLER, Vineet KUMAR, Ravi CHARI, Sonal SALUJA, Vishwesh PATIL
  • Patent number: 9670276
    Abstract: The disclosure provides binding proteins that specifically bind to IL-1? and IL-1?. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1? and/or IL-1? and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: June 6, 2017
    Assignee: AbbVie Inc.
    Inventors: Susan E. Lacy, Lorenzo Benatuil, Meha Chhaya, Emma Fung, Renee Miller, Ravi Chari, Sarah J. Heighton, Jacqueline G. Bixby
  • Publication number: 20170015742
    Abstract: Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.
    Type: Application
    Filed: June 15, 2016
    Publication date: January 19, 2017
    Inventors: Jijie GU, Diana BOWLEY, Lucia EATON, Feng DONG, Lorenzo BENATUIL, Tariq GHAYUR, Ravi CHARI, Matthew RIESER, Anca CLABBERS
  • Patent number: 9505829
    Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: November 29, 2016
    Assignee: ZOETIS BELGIUM S.A.
    Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
  • Publication number: 20160264656
    Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.
    Type: Application
    Filed: July 14, 2015
    Publication date: September 15, 2016
    Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari